Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
uniQure ( (QURE) ) just unveiled an announcement.
On June 11, 2025, uniQure held its Annual Meeting where shareholders voted on several key proposals. The meeting resulted in the re-election of Matthew Kapusta as executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting. Additionally, all other proposals, including the adoption of the 2024 Dutch statutory annual accounts, discharge of board members’ liabilities, and various authorizations related to shares and compensation, were approved.
The most recent analyst rating on (QURE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.
Spark’s Take on QURE Stock
According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.
uniQure demonstrates strong potential through regulatory progress and technical momentum, but faces substantial financial challenges. The strategic positioning in gene therapy offers growth opportunities, contingent on overcoming current revenue and profitability issues.
To see Spark’s full report on QURE stock, click here.
More about uniQure
Average Trading Volume: 1,808,605
Technical Sentiment Signal: Buy
Current Market Cap: $888M
For a thorough assessment of QURE stock, go to TipRanks’ Stock Analysis page.